• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI EvidencePulse™
  • Pharma
  • AI News
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI EvidencePulse™
  • Pharma
  • AI News
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home Wellness

Automated pupillometry may be helpful in opioid agonist therapy dosing for opioid use disorder

byNancy LuandAvneesh Bhangu
November 29, 2021
in Wellness
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. In this study, automated pupillometry demonstrated a significant change in mean pupil size detected within 15 minutes of opiate agonist therapy dosing amongst patients treated for opioid use disorder.

2. This study also found that there may be a threshold change in pupil size that may indicate good withdrawal symptom control.

Evidence Rating Level: 3 (Average) 

Many patients with opioid use disorder (OUD) find it difficult to manage due to withdrawal symptoms; thus, the dosage of opioid agonist therapy (OAT) needed to control withdrawal symptoms is an important question. Current protocols use the validated Clinical Opiate Withdrawal Scale (COWS), which includes a measurement of pupil size that has low precision and high interobserver variability. More precise measures of pupil size and reactivity could help eliminate this high interobserver variability. As such, this pilot study examined whether automated pupillometry may be more accurate in helping quantify opioid withdrawal amongst patients receiving OAT

This pilot study included patients aged 18-50 with OUD who were admitted to Boston Medical Center, Boston, Massachusetts, United States of America and received recommendations on OAT from the inpatient Addiction Consult Service between March and December 2018. Urine toxicology screening was performed to confirm opioid use. Participants were included if they consented to the pupillometry measurements, which were performed with the NeurOptics NPi-200 (n=27). Measured variables included pupil sizes (in light and dark illumination), latency of the pupillary light response, and percent constriction at varying timepoints pre-and post-OAT.

The analyses demonstrated a small but significant change in pupil size within 15 minutes of OAT administration when measured by the automated pupillometer, which persisted at later timepoints. Additionally, patients with well-controlled withdrawal symptoms had a significantly greater change in pupil size 60 minutes after OAT dosing compared to patients with high (therefore worse) COWS scores. This indicated there may be a threshold change in pupil size that corresponds with good symptom control. However, this pilot study was limited due to its small sample size which did not allow for sub-group analyses. Despite these limitations, this study demonstrated the potential viability of automated pupillometry in OAT dosing as a quantitative measure of withdrawal symptoms.

RELATED REPORTS

Higher dose extended-release buprenorphine improves outcomes in heavy fentanyl use

Integrating methadone into primary care improves care quality

2 Minute Medicine Rewind December 1st, 2025

Click to read the study in Journal of Addiction Medicine

Image: PD

©2021 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: COWSopioidopioid agonistopioid use disorderOUDpupillometry
Previous Post

Postoperative chemotherapy in chemosensitive patients undergoing surgical treatment of gastric cancer may prolong survival

Next Post

#VisualAbstract High cost of healthcare was the highest patient-reported barrier to accessing outpatient dermatologic care

RelatedReports

Patients with low back pain or pain at multiple sites at highest risk for chronic opioid use
Chronic Disease

Higher dose extended-release buprenorphine improves outcomes in heavy fentanyl use

December 22, 2025
Implementation of pneumococcal vaccine programs linked to decreased antibiotic prescription
Pharma

Integrating methadone into primary care improves care quality

December 8, 2025
Lariat device for left atrial appendage exclusion associated with adverse events
Weekly Rewinds

2 Minute Medicine Rewind December 1st, 2025

December 1, 2025
Parental nonmedical prescription opioid use linked to adolescent use
Pharma

Evidence gap for acute pain outcomes in opioid use disorder

March 24, 2025
Next Post
#VisualAbstract High cost of healthcare was the highest patient-reported barrier to accessing outpatient dermatologic care

#VisualAbstract High cost of healthcare was the highest patient-reported barrier to accessing outpatient dermatologic care

2 Minute Rewind November 29, 2021

2 Minute Rewind November 29, 2021

Avoiding screen time after concussion may shorten recovery time

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Ultrasound-Guided Regional Anesthesia by Emergency Physicians for Hip Fractures and Delirium
  • Ketamine, Etomidate, and Mortality in Emergency Department Intubations
  • Prognostic value of premaintenance FDG PET/CT response in patients with newly diagnosed myeloma from the CASSIOPEIA trial
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2025 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI EvidencePulse™
  • Pharma
  • AI News
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2025 2 Minute Medicine, Inc. - Physician-written medical news.